Fosun Pharma and Shanghai Institute of Materia Medica to Co-Develop Oncology Drug
Published: Nov 27, 2012
November 27, 2012 -- Shanghai Fosun Pharma and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, have agreed to jointly develop an innovative, small-molecule, triple-target oncology drug. The two entities will share the risk, the patent and benefits, though specific details of the arrangement were not disclosed. Fosun’s share of the research will be carried out by Chongqing Fochon Pharma, a subsidiary founded in 2009 by Dr. Weibo Wang. More details....
Stock Symbol: (SHA: 600196; HK: 2196)